Head-To-Head Comparison of Biological Behavior of Biocompatible Polymers Poly(Ethylene Oxide), Poly(2-Ethyl-2-Oxazoline) and Poly[N-(2-Hydroxypropyl)Methacrylamide] as Coating Materials for Hydroxyapatite Nanoparticles in Animal Solid Tumor Model.
animal model
hydroxyapatite
nanoparticles
poly(2-ethyl-2-oxazoline)
poly(ethylene oxide)
poly[N-(2-hydroxypropyl)methacrylamide]
solid tumor
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
27 Aug 2020
27 Aug 2020
Historique:
received:
04
08
2020
revised:
20
08
2020
accepted:
25
08
2020
entrez:
2
9
2020
pubmed:
2
9
2020
medline:
2
9
2020
Statut:
epublish
Résumé
Nanoparticles (NPs) represent an emerging platform for diagnosis and treatment of various diseases such as cancer, where they can take advantage of enhanced permeability and retention (EPR) effect for solid tumor accumulation. To improve their colloidal stability, prolong their blood circulation time and avoid premature entrapment into reticuloendothelial system, coating with hydrophilic biocompatible polymers is often essential. Most studies, however, employ just one type of coating polymer. The main purpose of this study is to head-to-head compare biological behavior of three leading polymers commonly used as "stealth" coating materials for biocompatibilization of NPs poly(ethylene oxide), poly(2-ethyl-2-oxazoline) and poly[
Identifiants
pubmed: 32867391
pii: nano10091690
doi: 10.3390/nano10091690
pmc: PMC7558523
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : 16-30544A
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : NU20-08-00095
Organisme : Ministry of Education, Youth and Sports of the Czech Republic
ID : EATRIS-CZ LM2015064 ERIC
Références
Drug Deliv Transl Res. 2019 Jun;9(3):721-734
pubmed: 30895453
Curr Top Med Chem. 2010;10(12):1227-36
pubmed: 20388106
Biomacromolecules. 2018 Jun 11;19(6):1732-1745
pubmed: 29690764
Drug Discov Today. 2014 Dec;19(12):1945-52
pubmed: 25205349
Ann Surg Oncol. 2015;22(6):1980-6
pubmed: 25391264
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
Nanoscale. 2017 Nov 9;9(43):16680-16688
pubmed: 29067394
Pharmaceutics. 2018 Oct 18;10(4):
pubmed: 30340364
Nanomedicine (Lond). 2019 May;14(10):1323-1341
pubmed: 31124758
Biomed Res Int. 2015;2015:676053
pubmed: 26075256
Sci Technol Adv Mater. 2019 Apr 15;20(1):324-336
pubmed: 31068982
Macromol Biosci. 2018 Jan;18(1):
pubmed: 28805040
J Clin Med. 2019 Dec 29;9(1):
pubmed: 31905769
Theranostics. 2017 Sep 26;7(17):4229-4239
pubmed: 29158822
Macromol Biosci. 2016 Nov;16(11):1577-1582
pubmed: 27654467
Front Pharmacol. 2018 Apr 27;9:421
pubmed: 29755355
Ci Ji Yi Xue Za Zhi. 2019 Jul-Sep;31(3):163-168
pubmed: 31258292
Colloids Surf B Biointerfaces. 2019 Jul 1;179:143-152
pubmed: 30954015
Macromol Rapid Commun. 2019 May;40(10):e1800917
pubmed: 30835923
Curr Opin Biotechnol. 2007 Feb;18(1):26-30
pubmed: 17254762
Mater Sci Eng C Mater Biol Appl. 2019 May;98:1252-1276
pubmed: 30813007
Nucl Med Commun. 2008 Mar;29(3):193-207
pubmed: 18349789
Nanomedicine. 2017 Feb;13(2):471-482
pubmed: 27720926
Theranostics. 2014 Jan 24;4(3):290-306
pubmed: 24505237
Nucl Med Commun. 2017 Jul;38(7):577-586
pubmed: 28591006
Biomaterials. 2017 Nov;146:1-12
pubmed: 28892751
Appl Radiat Isot. 2010 Dec;68(12):2117-24
pubmed: 20627742
Int J Clin Oncol. 2018 Dec;23(6):1167-1172
pubmed: 30094694
PLoS One. 2012;7(11):e48976
pubmed: 23152834
Theranostics. 2019 Oct 17;9(26):8073-8090
pubmed: 31754382